Spherix Uncovers Key Differences in the Management of Chronic Kidney Disease Patients in Europe Versus the U.S.
New analysis of European CKD non-dialysis patient chart data reveals notable differences in nephrologists’ use of renal therapies, including SGLT2 inhibitors EXTON, Pa., / April 25, 2022 / PRNewswire – The approval of several renal pipeline products in the European market has granted nephrologists new options through which they can manage their patients with chronic […]
IgA Nephropathy Market Shakes Up with Tarpeyo (Calliditas) Launch and Surge in Physician Prescribing of SGLT2 Inhibitors, Spherix Reports
Insights garnered from the newest launch report for Tarpeyo and recently published IgA nephropathy patient chart audit reveal shifting tides in the treatment landscape EXTON, Pa., March 28, 2021 /PRNewswire/ — IgA nephropathy (IgAN) is generally recognized as the most common glomerular nephritis disease globally, impacting many patients and often resulting in ESRD and dialysis […]
SGLT2 Inhibitors Are Gaining Momentum in Chronic and Diabetic Kidney Disease, New Spherix Data Reveals
Physician-reported and patient audit data reveal increased real world use of SGLT2 inhibitors (AstraZeneca’s Farxiga, Vifor/Janssen’s Invokana, Eli Lilly/Boehringer Ingelheim’s Jardiance and Merck’s Steglatro) among nephrologists’ CKD and DKD patients EXTON, Pa., / March 8, 2022 / PRNewswire – Nephrologists have historically had few options to help slow the progression of kidney disease in their […]
Spherix Global Insights Embarks on Its Fifth Year of Extensive ADPKD Coverage as the Market Heats Up
Armed with fresh insights from their patient chart audit, Spherix focuses on market trending and evolving perceptions of pipeline agents for ADPKD EXTON, Pa., February 3, 2022 /PRNewswire/ — Autosomal dominant kidney disease (ADPKD) is a life-threatening genetic disease that causes fluid-filled cysts to develop and enlarge in both kidneys. With only one FDA-approved treatment (Otsuka’s […]
Perceptions and Prescribing Patterns of GSK’s Benlysta and Aurinia’s Lupkynis Highlight an Increasing Divide Among Nephrologists and Rheumatologists, Spherix Finds
Approaching one year on the market to treat lupus nephritis, comprehensive launch coverage reveals a widening gap in attitudes and use of the two new products EXTON, Pa., December 14, 2021 /PRNewswire/ — The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus,[1] and as […]
Implications of Expanded Biosimilar Use in the United States’ Dermatology, Gastroenterology, Rheumatology, Ophthalmology, Nephrology, and Neurology Markets Highlighted in New Spherix Study
450 US specialists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment landscape EXTON, Pa., December 8, 2021 /PRNewswire/ – Biosimilars are biopharmaceutical products that are nearly identical copies of drugs that have previously been licensed (reference products), with no clinically meaningful efficacy and safety differences from […]
More Than 2,000 Patient Chart Records Reveal Shifting Tides in Kidney Patient Care
Implications abound for historic leader Amgen and newer companies with paradigm-shifting SGLT2 inhibitors (AstraZeneca [Farxiga], Vifor/Janssen [Invokana], Eli Lilly/Boehringer Ingelheim [Jardiance] and Merck [Steglatro]) EXTON, Pa., / December 7, 2021/ PRNewswire – Chronic kidney disease (CKD) patients experience a wide range of comorbidities and risks associated with their disease, such as hyperphosphatemia, secondary hyperparathyroidism (SHPT), […]
Renal Anemia Market Revs Up in Europe With the Launch of FibroGen Inc’s/Astellas Pharma’s EVRENZO (Roxadustat), Spherix Global Insights Reports
Content Area
Novel Agents in Systemic Lupus Erythematosus (AstraZeneca’s anifrolumab) and Lupus Nephritis (Aurinia Pharmaceutical’s voclosporin and GSK’s belimumab) Introduce Paradigm Shifts
New launch tracking reports and patient audit data show early excitement and ample opportunity for the latest approvals as well as several pipeline agents (including Eli Lilly’s baricitinib in SLE and Roche-Genentech’s obinutuzumab in LN) garnering high interest among rheumatologists and nephrologists November 4, 2021, EXTON, PA – After nearly a decade of stagnant innovation […]
Disparities in Kidney Care: Where Care Needs to Be Equal
Authors: Meghan Staudt, Skylar Malone, Tucker Hurtado BACKGROUND: Disparities in kidney care are widespread and gaining more attention. This research focuses on care differences that existed between home hemodialysis (HHD) and in-center hemodialysis (ICHD) patient from 2017 to 2020. METHODS: Using a HIPAA-compliant, online chart review tool, nephrologists submitted de-identified clinical and non-clinical demographic information […]
